Herein provided are dosage forms (variously referred to as "formulations") comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
申请公布号
WO2006009602(A2)
申请公布日期
2006.01.26
申请号
WO2005US19028
申请日期
2005.06.01
申请人
TAP PHARMACEUTICAL PRODUCTS, INC.;TANEJA, RAJNEESH;VAKILYNEJAD, MAJID